Date: Sunday, June 12, 2016
Session Name: Poster Session B: Kidney: Cardiovascular and Metabolic
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Previous studies demonstrated the significance of angiotensin II type-1 receptor antibodies (AT1Rabs) in processes including hypertension, cardiac hypertrophy and renal fibrosis; information regarding ventricular and endothelial dysfunction is lacking and constitute the aim of this study. Methods: AT1Rabs were determined (CellTrend GmBH, One-Lambda) in pretransplant sera samples from renal transplant recipients (RTR); AT1Rabs titers ≥17U were considered positive. At a median of 42.9±9.07 mo posttransplantation endothelial function was measured by photoplethysmography (PPG) using the index waveform maximum amplitude time/total amplitude time (MAT/TT); a MAT/TT >30 was defined as endothelial dysfunction (ED). In order to evaluate cardiac function a transthoracic echocardiogram (TTE) was also performed pretransplant and posttransplant at a median of 24.8±15.9 mo, where the mean parameter valued was left ventricular ejection fraction (LVEF). Results: The study included 67 RTR with pre- and posttransplant TTE. Patients were divided in 2 groups according to AT1Rabs results (positive (+ve) (n=8) or negative (-ve) (n=59). A lower pre-transplant LVEF was found in AT1Rab+-ve RTR as well as a higher frequency of endothelial dysfunction compared to AT1Rab-ve RTR. Improvement in LVEF posttransplant occurred in both groups however LVEF continue being higher in the ATRabs-ve group. Also, dyslipidemia (defined according to ACC/AHA criteria) was significantly more frequent in AT1Rab+ive patients. There were no significant differences in the demographic characteristics between the groups (Table 1), neither in confounding factors for endothelial dysfunction.
|Age (yr)||34.3 (±10.5)||32.8 (±12.1)||0.71|
|Gender (male) %||70||53.2||0.3|
|LVEF (%) pretransplant||50 (±18)||61.8 (±9.8)||0.005|
|LVEF (%) posttransplant||59.1 (±14)||62.1 (±8)||0.009|
|ED (n=44)||2 (40)||4 (10)||0.13|
Conclusions: There were lower pre- & posttransplant LVEF, a trend toward worse endothelial function and a significantly different frequency of dyslipidemia in RTR AT1Rabs+ve patients. Whether AT1Rabs represents a greater risk for CV outcome of this population remain to be defined.
CITATION INFORMATION: Figuerola-Chaparro L, Davila-Radilla F, Cuevas E, Castillo-Martínez L, Orea-Tejeda A, Arreola-Guerra J, Alberu J. Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Figuerola-Chaparro L, Davila-Radilla F, Cuevas E, Castillo-Martínez L, Orea-Tejeda A, Arreola-Guerra J, Alberu J. Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/angiotensin-ii-type-1-receptor-antibodies-in-renal-transplant-recipients-associated-with-ventricular-and-endothelial-dysfunction-preliminary-results/. Accessed March 4, 2021.
« Back to 2016 American Transplant Congress